Comprehensive Overview of GLP-1 RAs in Cardiometabolic Care
![](https://www.cardiometabolichealth.org/wp-content/uploads/2024/02/Comprehensive-Overview-of-GLP-1-022924-01-1-1024x444.jpg.webp)
The not-so-sudden rise of weight loss ”wonder” drugs for T2D and obesity This World Obesity Day, March 4, 2024, weight loss drugs dominate discussions and raise new questions for clinicians. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have been used to treat type 2 diabetes (T2D) since the approval of Byetta (exenatide) in 2005. In the […]